title: Successful treatment of intraocular post-transplant lymphoproliferative disorder with intravenous rituximab.
abstract: We reported a rare case of intraocular post-transplant lymphoproliferative disorder (PTLD) arising in a 3-year-old liver transplant recipient who had a prior history of systemic PTLD. The first PTLD entered remission after treatment with intravenous rituximab and withdrawal of immunosuppressants. One year after remission, she presented with granulomatous uveitis and iris nodules in the right eye. Iris biopsy confirmed recurrence of intraocular PTLD, which resolved completely after a second course of intravenous rituximab.
authors.affiliation: Department of Ophthalmology, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
authors.forename: Lawrence P
authors.initials: LP
authors.lastname: Iu
authors.forename: Jane C
authors.initials: JC
authors.lastname: Yeung
authors.forename: Florence
authors.initials: F
authors.lastname: Loong
authors.forename: Alan K
authors.initials: AK
authors.lastname: Chiang
mesh_terms: D061605:Administration, Intravenous; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001656:Biliary Atresia / Q000150:complications* / Q000601:surgery; D002675:Child, Preschool; D005128:Eye Diseases / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007429:Intraocular Pressure / Q000187:drug effects; D016031:Liver Transplantation / Q000009:adverse effects*; D008232:Lymphoproliferative Disorders / Q000188:drug therapy* / Q000209:etiology; D011183:Postoperative Complications / Q000188:drug therapy* / Q000209:etiology; D011379:Prognosis; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D000069283:Rituximab
keywords: anti-CD20 antibody; intraocular; post-transplant lymphoproliferative disorder (PTLD); rituximab